Brief: Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
05/12/2023 13:23
Dec 5 (Reuters) - Aquestive Therapeutics Inc AQST.O :
* AQUESTIVE THERAPEUTICS DOSES FIRST PATIENT IN PHASE 3
PIVOTAL
CLINICAL STUDY EVALUATING PHARMACOKINETICS AND PHARMACODYNAMICS
OF ANAPHYLM™ (EPINEPHRINE) SUBLINGUAL FILM
* AQUESTIVE THERAPEUTICS INC - REAFFIRMS TOPLINE DATA
ANTICIPATED
IN Q1 2024
* AQUESTIVE THERAPEUTICS INC - COMMENCES INITIAL PHASE 3
STUDY
WITH FIRST ORALLY DELIVERED EPINEPHRINE PRODRUG CANDIDATE
Source text for Eikon: ID:nGNX3dhlkc
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million